Bridgeway Capital Management, LLC Candel Therapeutics, Inc. Transaction History
Bridgeway Capital Management, LLC
- $3.98 Billion
- Q2 2025
A detailed history of Bridgeway Capital Management, LLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 55,100 shares of CADL stock, worth $349,885. This represents 0.01% of its overall portfolio holdings.
Number of Shares
55,100Holding current value
$349,885% of portfolio
0.01%Shares
7 transactions
Others Institutions Holding CADL
# of Institutions
84Shares Held
15.3MCall Options Held
570KPut Options Held
203K-
Acorn Capital Advisors, LLC New York, NY2.58MShares$16.4 Million8.54% of portfolio
-
Northpond Ventures, LLC1.94MShares$12.3 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.79MShares$11.4 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.62MShares$10.3 Million0.59% of portfolio
-
Geode Capital Management, LLC Boston, MA904KShares$5.74 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $183M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...